Woodcock steps away from CDER for Operation Warp Speed; Marks back to CBER
Leadership shuffle at FDA to support government and company programs against COVID-19
In a major reorganization intended to better align FDA’s activities with the national effort to develop COVID-19 countermeasures, Janet Woodcock is temporarily stepping away from her position as director of FDA’s Center for Drug Evaluation and Research, and Peter Marks is stepping away from his role as lead of vaccines at Operation Warp Speed.
Woodcock will be detailed to FDA’s Office of the Commissioner. ...